Syra Health Announces Positive Preliminary Results from Syrenity Study Led by Indiana University
Syra Health (NASDAQ: SYRA) announced positive preliminary results from a clinical research study of its mental health app, Syrenity, conducted by Indiana University. The randomized study involved 135 participants with moderate or severe depression symptoms, with 63 given access to Syrenity and 72 without.
The six-week study showed promising trends in reducing depression symptoms among Syrenity users compared to non-users. Improvements were noted in cognitive reappraisal and emotion expression. The study population consisted of approximately two-thirds women, 30% racial-ethnic minorities, and 50% with bachelor's degrees or higher.
According to Dr. Lorenzo-Luaces, principal investigator, Syrenity is among less than 5% of mental health apps based on science and uniquely addresses multiple mental health conditions. A second clinical study is planned to test statistical significance, with results intended for publication in a scientific journal.
Syra Health (NASDAQ: SYRA) ha annunciato risultati preliminari positivi da uno studio di ricerca clinica sulla sua app per la salute mentale, Syrenity, condotto dall'Università dell'Indiana. Lo studio randomizzato ha coinvolto 135 partecipanti con sintomi di depressione moderata o grave, di cui 63 hanno avuto accesso a Syrenity e 72 no.
Lo studio di sei settimane ha mostrato tendenze promettenti nella riduzione dei sintomi depressivi tra gli utenti di Syrenity rispetto ai non utenti. Sono stati notati miglioramenti nella rivalutazione cognitiva e nell'espressione delle emozioni. La popolazione dello studio era composta da circa due terzi di donne, il 30% di minoranze razziali ed etniche e il 50% con laurea o titolo superiore.
Secondo il Dr. Lorenzo-Luaces, ricercatore principale, Syrenity è tra meno del 5% delle app per la salute mentale basate su evidenze scientifiche e affronta in modo unico molteplici condizioni di salute mentale. È previsto uno studio clinico secondario per testare la significatività statistica, con risultati destinati alla pubblicazione su una rivista scientifica.
Syra Health (NASDAQ: SYRA) anunció resultados preliminares positivos de un estudio de investigación clínica sobre su aplicación de salud mental, Syrenity, realizado por la Universidad de Indiana. El estudio aleatorizado involucró a 135 participantes con síntomas de depresión moderada o severa, de los cuales 63 tuvieron acceso a Syrenity y 72 no.
El estudio de seis semanas mostró tendencias prometedoras en la reducción de síntomas de depresión entre los usuarios de Syrenity en comparación con los no usuarios. Se notaron mejoras en la reevaluación cognitiva y la expresión emocional. La población del estudio consistía en aproximadamente dos tercios de mujeres, un 30% de minorías raciales y étnicas, y un 50% con títulos de licenciatura o superiores.
Según el Dr. Lorenzo-Luaces, investigador principal, Syrenity se encuentra entre menos del 5% de las aplicaciones de salud mental basadas en la ciencia y aborda de manera única múltiples condiciones de salud mental. Se planea un segundo estudio clínico para probar la significancia estadística, con resultados destinados a su publicación en una revista científica.
Syra Health (NASDAQ: SYRA)는 인디애나 대학교에서 수행한 정신 건강 앱 Syrenity에 대한 임상 연구의 긍정적인 초기 결과를 발표했습니다. 무작위 연구에는 중증 또는 심각한 우울증 증상을 가진 135명의 참가자가 포함되었으며, 이 중 63명이 Syrenity에 접근할 수 있었고 72명은 접근할 수 없었습니다.
6주간의 연구는 Syrenity 사용자가 비사용자에 비해 우울증 증상을 줄이는 데 유망한 경향을 보였습니다. 인지 재평가 및 감정 표현에서 개선이 관찰되었습니다. 연구 대상 집단은 약 3분의 2가 여성, 30%가 인종적 및 민족적 소수자, 50%가 학사 이상의 학위를 가진 것으로 구성되었습니다.
주요 연구자인 로렌조-루아세스 박사에 따르면, Syrenity는 과학에 기반한 정신 건강 앱의 5% 미만에 해당하며 여러 정신 건강 상태를 독특하게 다룹니다. 통계적 유의성을 테스트하기 위한 두 번째 임상 연구가 예정되어 있으며, 결과는 과학 저널에 게재될 예정입니다.
Syra Health (NASDAQ: SYRA) a annoncé des résultats préliminaires positifs d'une étude de recherche clinique sur son application de santé mentale, Syrenity, réalisée par l'Université de l'Indiana. L'étude randomisée a impliqué 135 participants présentant des symptômes de dépression modérée ou sévère, dont 63 ont eu accès à Syrenity et 72 non.
L'étude de six semaines a montré des tendances prometteuses dans la réduction des symptômes dépressifs chez les utilisateurs de Syrenity par rapport aux non-utilisateurs. Des améliorations ont été notées dans la réévaluation cognitive et l'expression émotionnelle. La population de l'étude était composée d'environ deux tiers de femmes, de 30% de minorités raciales et ethniques, et de 50% ayant un diplôme de licence ou supérieur.
Selon le Dr Lorenzo-Luaces, chercheur principal, Syrenity figure parmi moins de 5% des applications de santé mentale basées sur des données scientifiques et aborde de manière unique plusieurs conditions de santé mentale. Une deuxième étude clinique est prévue pour tester la signification statistique, avec des résultats destinés à être publiés dans une revue scientifique.
Syra Health (NASDAQ: SYRA) gab positive vorläufige Ergebnisse einer klinischen Forschungsstudie zu seiner Mental Health-App Syrenity, die von der Universität Indiana durchgeführt wurde, bekannt. Die randomisierte Studie umfasste 135 Teilnehmer mit moderaten oder schweren Depressionen, von denen 63 Zugang zu Syrenity hatten und 72 nicht.
Die sechs Wochen dauernde Studie zeigte vielversprechende Trends zur Verringerung der Depressionssymptome bei Syrenity-Nutzern im Vergleich zu Nicht-Nutzern. Verbesserungen wurden in der kognitiven Neubewertung und im emotionalen Ausdruck festgestellt. Die Studienpopulation bestand aus etwa zwei Dritteln Frauen, 30% ethnischen Minderheiten und 50% mit einem Bachelor-Abschluss oder höher.
Laut Dr. Lorenzo-Luaces, dem Hauptforscher, gehört Syrenity zu weniger als 5% der wissenschaftlich basierten Mental Health-Apps und behandelt auf einzigartige Weise mehrere psychische Gesundheitszustände. Eine zweite klinische Studie ist geplant, um die statistische Signifikanz zu testen, wobei die Ergebnisse zur Veröffentlichung in einer wissenschaftlichen Zeitschrift vorgesehen sind.
- Preliminary clinical study shows positive trends in reducing depression symptoms
- App is among less than 5% of mental health apps with scientific basis
- Product addresses multiple mental health conditions simultaneously
- Study demonstrates improvements in cognitive reappraisal and emotion expression
- Results are preliminary and require further validation through additional studies
- Statistical significance of results not yet established
Insights
The clinical study of Syrenity represents a significant development in the digital mental health space, with several noteworthy aspects that differentiate it from typical app trials. The study's design, led by Indiana University, demonstrates robust academic rigor through its randomized controlled approach and diverse participant pool.
The preliminary results reveal three critical outcomes:
- Reduced depression symptoms in the treatment group
- Improved cognitive reappraisal abilities
- Enhanced emotional regulation
What's particularly compelling is that Syrenity belongs to the elite
The study's demographic composition is strategically valuable, with significant representation from key market segments:
- Two-thirds female participants, aligning with higher mental health app adoption rates among women
30% racial-ethnic minorities, supporting potential market expansion- Diverse socioeconomic representation, suggesting broad applicability
The planned second clinical study and intended peer-reviewed publication will be important for establishing Syrenity's clinical credibility. This evidence-based approach could significantly impact B2B sales cycles, particularly with healthcare systems and employers seeking validated mental health solutions.
The multi-condition targeting capability addresses a critical gap in the market, as comorbid depression and anxiety are common but often inadequately addressed by single-focus applications. This feature could drive higher user retention and better clinical outcomes, potentially leading to stronger recurring revenue streams.
A randomized clinical research study to test the efficacy of the Syrenity app is being led by Dr. Lorenzo-Luaces, principal investigator and associate department chair of Psychological and Brain Sciences at IU. The IRB-approved study enrolled approximately 135 people who expressed symptoms of moderate or more severe depression. Of the 135 people, 63 were provided access to Syrenity versus 72 people without access. The preliminary analysis of the six-week study suggested trends toward reductions in depression symptoms among Syrenity users compared to those without access to the app. Preliminary trends in overall well-being were also observed, alongside indications of increased cognitive reappraisal—or the ability to mentally reframe experiences to avoid negative emotions. There were also signs of improvement in emotion suppression (expressive suppression), an unhealthy coping strategy where a person hides their feelings to try and make themselves feel better. Participants who used the Syrenity app were more likely to show their emotions in a healthy way than non-app users.
"I'm very excited about the app because it's one of fewer than
A second clinical research study with additional users will be conducted in due course to test the statistical significance of these results. A detailed analysis of engagement measures and a qualitative analysis of users will be performed to further understand the app's efficacy. The results of these analyses will help in developing additional modules, new features, and activities targeting various behavioral and mental health issues.
Of the study participants, roughly two-thirds were women, approximately
"We are encouraged by the preliminary results of the Syrenity research study," said Dr. Deepika Vuppalanchi, chair and CEO of Syra Health. "We recognize that traditional approaches don't work for all the millions of people suffering from depression and anxiety, and we are thrilled to offer a solution that integrates psychology and technology."
Syra Health plans to publish the results of the Syrenity clinical study in a scientific journal. Syrenity is available as a business-to-business product and for direct download by adults on the App Store or Google Play Store.
About Syra Health
Syra Health is a healthcare technology company powering better health in critical areas such as behavioral and mental health, population health, and the healthcare workforce. The company's leading-edge technology and innovative services focus on prevention, access, and affordability. With a commitment to improving health, Syra Health is advancing healthcare solutions nationwide and around the world.
About Syrenity
Syrenity is a scientifically-based mental and behavioral health app developed by Syra Health that uniquely addresses mental health needs through its dual focus on prevention and intervention. The app begins with thorough scientific assessments to identify mental health risks early. Syrenity's sophisticated algorithms provide symptom monitoring scores, helping prevent the escalation of various mental health conditions. Tailored to each user's needs, Syrenity offers evidence-based interventions such as cognitive behavioral therapy, targeted psychoeducation, and more. The app features an AI-driven companion, Echo, that prompts users to reflect and engage, responding with empathy and encouragement. Syrenity also generates two real-time AI reports: one for tracking progress and another for actionable insights.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For Media or Investor Inquiries:
Christine Drury
IR/PR
Syra Health
463-345-5180
christined@syrahealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-announces-positive-preliminary-results-from-syrenity-study-led-by-indiana-university-302378408.html
SOURCE Syra Health
FAQ
What are the preliminary results of Syra Health's (SYRA) Syrenity app clinical study?
How many participants were included in SYRA's Syrenity app clinical trial?
What distinguishes Syra Health's (SYRA) Syrenity app from other mental health apps?
What is the demographic breakdown of SYRA's Syrenity app study participants?
When will SYRA conduct the second clinical study for the Syrenity app?
